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[Abstract] Blood platelets are critical for hemostasis and thrombosis, but also play diverse roles during 
immune responses. We have recently reported that platelets migrate at sites of infection in vitro and in 
vivo. Importantly, platelets use their ability to migrate to collect and bundle fibrin (ogen)-bound bacteria 
accomplishing efficient intravascular bacterial trapping. Here, we describe a method that allows 
analyzing platelet migration in vitro, focusing on their ability to collect bacteria and trap bacteria under 
flow. 
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[Background] Platelets are small, anucleate cellular fragments released from megakaryocytes that 
reside within the bone marrow of mammalian organisms (Machlus and Italiano, 2013). Approximately 
750 billion platelets circulate in human blood, constantly scanning the vasculature for damage of the 
endothelial surface. Upon encountering endothelial injury, platelets are immediately recruited in a well-
characterized cascade of events including initial platelet tethering and rolling, followed by platelet activation, 
adhesion and spreading, eventually leading to fibrin (ogen)-dependent aggregation and subsequent 
thrombus retraction (Jackson, 2007). Platelet plug formation is a major step in physiological hemostasis, 
but also in pathological thrombosis after atherosclerotic plaque rupture, triggering myocardial infarction or 
stroke (Jackson, 2011). 
  In addition to their well-established role in hemostasis and thrombosis, platelets also evolved diverse 
immunologic functions (Semple et al., 2011). Being among the first cells recruited to sites of inflammation 
and infection, platelets play an essential role in initiating intravascular immune responses (Wong et al., 
2013). Accordingly, platelets coordinate the recruitment of a variety of immune cells and instruct them with 
their effector programs (Sreeramkumar et al., 2014). Platelets also have the ability to directly fight 
pathogens by releasing anti-microbial mediators and/or physically trapping and encapsulating invaders, 
thus preventing dissemination with the blood flow (Yeaman, 2014). 
  We recently identified platelet migration as an autonomous platelet function and showed that migration 
of single platelets provides a mechanism of controlling their interaction with pathogenic bacteria within the 
microcirculation (Gaertner et al., 2017). Once adhering to immobilized fibrin (ogen), activated platelets 
use αIIbβ3 integrins to probe the resistance of their local microenvironment. When actomyosin-
dependent traction forces overcome substrate resistance platelets eventually polarize and migrate 
thereby removing and accumulating platelet-bound ligands. As a prominent example, migrating platelets 
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collect and bundle fibrin (ogen)-bound bacteria accomplishing efficient intravascular bacterial trapping. 
In contrast to phagocytes like neutrophils, platelets behave like “covercytes” that do not internalize 
collected bacteria but rather accumulate them on their surface within invaginations of the plasma 
membrane (White, 2005). When exposed to shear stress in vitro platelets strongly bind to piled-up 
bacteria. 
  Here we provide a detailed protocol for the isolation of platelets from human blood and microscopic 
observation of platelet migration and trapping of Escherichia coli (E. coli) under flow. 
 
Materials and Reagents 
 
1. Pipette tips 0.1-10 μl (Eppendorf, epT.I.P.S.® Reloads, catalog number: 022491504) 
2. Pipette tips 0.5-20 μl (Eppendorf, epT.I.P.S.® Reloads, catalog number: 022491521) 
3. Pipette tips 2-200 μl (Eppendorf, epT.I.P.S.® Reloads, catalog number: 022491539) 
4. Pipette tips 50-1,000 μl (Eppendorf, epT.I.P.S.® Reloads, catalog number: 022491555) 
5. 15 ml Falcon tube (Corning, catalog number: 352096) 
6. Tygon 3350 silicone tube (Saint-Gobain Performance Plastics, catalog number: ABW00002) 
7. Safety-Multifly-Needle 21G (SARSTEDT, catalog number: 85.1638.935) 
8. Membrane adaptor (SARSTEDT, catalog number: 14.1112) 
9. 5 ml syringes (BD, Discardit IITM, catalog number: 301285) 
10. 50 ml syringes (BD, perfusion, catalog number: 300136) 
11. Bottomless 6 channel sticky slide (IBIDI, sticky slides VI0.4, catalog number: 80608) 
12. Glass coverslips 24 mm x 24 mm (SCHOTT, NEXTERION®, No. 1.5, catalog number: D263T) 
13. Cuvette (Eppendorf, catalog number: 952010069) 
14. Human blood (taken from male and female healthy donors with the age of 25-40 years old) 
15. Plasmid ptdTomato (Takara Bio, catalog number: 632531) 
16. E. coli strains (DH12S, Invitrogen) 
E. coli was transformed with plasmid ptdTomato. TdTomato is encoded within the lac operon 
and transcription is induced in the presence of isopropylthio-β-galactoside (IPTG) (IPTG binds 
to the lac repressor and releases lac repressor from the lac operator). The plasmid carries the 
bla-gene for ampicillin resistance. 
Note: E. coli stock was made in LB with 7% dimethyl sulfoxide (v/v) and kept at -80 °C. 
17. Distilled water (ddH2O) (Millipore) 
18. Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, catalog number: D2438) 
19. Phosphate buffered saline (PBS) (Sigma-Aldrich, catalog number: D8537) 
20. Recombinant human albumin (rHSA) (Sigma-Aldrich, catalog number: A9731) 
Note: Dissolve rHSA in ddH2O to 8% (w/v) solution and store the aliquots at -20 °C. 
21. Prostaglandin I2 sodium salt (PGI2) (Abcam, catalog number: ab120912) 
Note: Dissolve it in DMSO to 10 mg/ml and store the aliquots at -20 °C. 
22. HEPES solution (Sigma-Aldrich, catalog number: H0887) 
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23. 20% HNO3 (Carl Roth, catalog number: 4337.2) 
24. Hexamethyldisilazane (HMDS) (Sigma-Aldrich, catalog number: 440191) 
25. Fibrinogen from human plasma (Sigma-Aldrich, catalog number: F3879) 
Note: Dissolve it in 0.9% NaCl to 2 mg/ml and store the aliquots at -20 °C. 
26. Fibrinogen from human plasma, Alexa Fluor 488 conjugate (Thermo Fisher Scientific, Life 
technology, catalog number: F13191) 
Note: Dissolve it in 0.1 M NaHCO3 (pH 8.3) to 1.5 mg/ml and store the aliquots at -20 °C. 
27. U46619 (Enzo Life Sciences, catalog number: BML-PG023-0001) 
Note: Dissolve it in DMSO to 28.8 mM and store the aliquots at -20 °C. 
28. Adenosine 5′-diphosphate sodium salt (ADP) (Sigma-Aldrich, catalog number: A2754) 
Note: Dissolve it in PBS to 20 mM and store the aliquots at -20 °C. 
29. Thrombin from bovine plasma (Sigma-Aldrich, catalog number: T4648) 
Note: Dissolve it in 0.1% (w/v) bovine serum albumin (BSA) to 100 U/ml and store the aliquots 
at -20 °C. 
30. LB broth (Sigma-Aldrich, catalog number: L3022) 
Note: 20 g LB powder was dissolved in 1 L ddH2O and autoclaved. 
31. Isopropyl β-D-1-thiogalactopyranoside (IPTG) (Sigma-Aldrich, catalog number: I6758) 
Note: Dissolve IPTG in ddH2O to 100 mM and store the aliquots at -20 °C. 
32. Ampicillin sodium salt (Sigma-Aldrich, catalog number: A9518) 
Note: Dissolve ampicillin in ddH2O to 50 mg/ml and store the aliquots at -20 °C. 
33. Sodium citrate tribasic dehydrate (C6H5Na3O7·2H2O) (Sigma-Aldrich, catalog number: S4641) 
34. Citric acid monohydrate(C6H8O7·H2O) (Sigma-Aldrich, catalog number: C1909) 
35. Glucose (Merck, Calbiochem, catalog number: 346351) 
36. Sodium chloride (NaCl) (Carl Roth, catalog number: 3957.3) 
37. Sodium bicarbonate (NaHCO3) (Merck, catalog number: 106329) 
38. Potassium chloride (KCl) (Carl Roth, catalog number: 6781.3) 
39. Calcium chloride (CaCl2) (Sigma-Aldrich, catalog number: C8106) 
Note: CaCl2·2H2O was dissolved in ddH2O to make 100 mM stock solution and stored at 4 °C. 
40. Acid-citrate-dextrose (ACD) buffer, pH 4.7 (see Recipes) 
41. Modified Tyrode’s buffer (see Recipes) 
42. Fibrin buffer (see Recipes) 
  
Equipment 
 
1. Pipette 0.1-2.5 μl (e.g., Eppendorf, Research plus: O18485E) 
2. Pipette 0.5-10 μl (e.g., Eppendorf, Research plus: O30964E) 
3. Pipette 10-100 μl (e.g., Eppendorf, Research plus: O30379E) 
4. Pipette 100-1,000 μl (e.g., Eppendorf, Research plus: O29260E) 
5. Orbi-Shaker (e.g., Benchmark) 
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6. pH meter (e.g., Mettler Toledo) 
7. BioPhotometer (e.g., Eppendorf, model: BioPhotometer 6131) 
8. Bunsen burner (e.g., Campingaz) 
9. Centrifuge (e.g., Eppendorf, model: 5804) 
10. Cell culture incubator (e.g., Binder) 
11. Hematology counter (e.g., Horiba Medical) 
12. KLM spin coater (e.g., Schaefer) 
13. Inverted phase contrast and fluorescent microscope (e.g., OLYMPUS, model: IX83) 
14. Syringe pump (e.g., KD Scientific, model: KDS 100) 
 
Software 
 
1. Live cell imaging software that was connected to the microscope (e.g., CellSense) 
2. Fiji software [National Institutes of Health (NIH)] 
 
Procedure 
 
A. Isolation of washed platelets 
1. Take human blood from cubital vein by safety multifly-needle on volunteers. Discard the first 1 
ml then take another 5 ml into a syringe with 714 μl ACD buffer (see Recipe 1) inside. 
Notes:  
a. The volunteers should not take any drugs that affect platelets in the last two weeks. 
b. Draw blood smoothly to avoid platelets activation. 
2. Mix the blood with an equal volume of modified Tyrode’s buffer (pH 6.5) (see Recipe 2) in a 15 
ml falcon tube. 
3. Centrifuge the mixture in Step A2 at 70 x g for 35 min without brake at room temperature (RT) 
to obtain platelet-rich plasma (PRP) retrieved from the upper layer. 
4. Mingle 3 ml PRP with 7 ml modified Tyrode’s buffer (pH 6.5) in the presence of 0.1% rHSA (w/v) 
and 100 ng/mg PGI2 in a 15 ml Falcon tube. 
5. Centrifuge the diluted PRP in Step A4 at 1,200 x g for 10 min at RT. 
6. Discard the supernatant and suspend the pellet carefully in 1 ml Tyrode’s buffer with pH 6.5. 
7. Measure the platelet concentration on an automated hematology counter. 
8. Store the purified platelets at room temperature until use.  
Notes:  
a. Platelets cannot be cultured, so they should be prepared daily from freshly drawn blood. 
b. The whole process of platelets preparation should be gentle enough to prevent platelets 
activation. 
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B. Bacteria preparation 
1. Inoculate E. coli from a frozen stock in LB-broth medium with 100 μg/ml Ampicillin. 
Note: Conduct E. coli inoculation at the Bunsen burner. 
2. Culture the inoculated E. coli at 37 °C with 260 rpm shaking overnight. 
3. On the following day, dilute saturated culture of E. coli in LB-broth medium with 1 mM IPTG and 
100 μg/ml Ampicillin (1:500 in a volume of 5 ml). 
4. Culture the diluted E. coli in Step B3 at 37 °C with 260 rpm for 2.5 h to allow growth to mid-log 
phase.  
5. Determine the colony forming units (CFU)/ml of cultured E. coli at OD600nm=1 (1, Determine 
viability of bacteria as a function of OD600nm by plating bacteria and counting colony forming 
units at various time points with increasing OD600nm. 2, Based on obtained growth curves 
determine CFUs/ml at OD600nm=1, we obtained 2.8 x 108 CFU/ml at OD600nm = 1.0). 
6. Measure the E. coli concentration by optical density at OD600nm (expected OD600nm ~0.5-0.6). 
7. Adjust the cultured E. coli to OD600nm equal to 0.25 in LB medium (0.7 x 108 CFU/ml; 1 ml), 
centrifuge at 1,200 x g for 5 min and discard the supernatant. 
8. Suspend the bacteria pellet in equal volume of PBS (1 ml) and keep them on ice under light 
protection until use. 
Note: Perform the bacteria preparation according to the safety regulations of your laboratory. 
 
C. Coverslip coating 
1. Immerse glass coverslips in 20% HNO3 for 1 h on a shaker with the speed set at 60 rpm, then 
wash with ddH2O four times. 
2. Soak acid-washed coverslips in ddH2O for another 1 h on the same shaker, and rinse again 
with ddH2O twice. 
3. Dry the freshly cleaned coverslips at 90 rps for 10 sec by a KLM spin coater. 
4. Silanize air-dried coverslips with HMDS at 80 rps for 30 sec using a spin coater to ensure 
homogeneous silanization. 
Note: HMDS is volatile and inflammable, so coat the HMDS in a ventilation hood. 
5. Cut the 6 channel bottomless Ibidi sticky-slide into single channel slides (Figure 1), and mount 
to the silanized coverslip. 
Note: Mount coverslips and sticky-slide with some pressure until the bottom is sealed, otherwise 
the buffer in the channel will leak out. 
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Figure 1. A photo of Ibidi sticky slides. The upper is the 6-channel slide; the lower is the 6- 
cutted single slides. 
 
6. Seed 120 μl prepared E. coli (8.4 x 106 CFUs) in PBS on silanized coverslip in the Ibidi channel 
at 37 °C for 30 min. 
7. Coat 120 μl fibrin (see Recipe 4) on the E. coli seeded coverslip for 15 min at RT. 
8. Wash the fibrin-coated slides 5 times with modified Tyrode’s buffer (pH 7.4; 120 μl) (Figures 2 
and 3). 
 
 
Figure 2. Diagram of the experimental setup. The single Ibidi sticky slide channel is mounted 
on a silanized glass coverslip. The buffer is pipetted as indicated by the red arrows. 
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Figure 3. A representative coverslip coated with fibrin and bacteria. Freshly cleaned and 
silanized glass coverslip was seeded with E. coli and incubated at 37 °C for 30 min, then coated 
with fibrin for 15 min at RT, and finally washed with Tyrode’s buffer. A. Phase contrast image of 
the coated channel. B. Fluorescent fibrin coating of the channel. C. Fluorescent E. coli bound 
to the channel. D. Merged channels. Scale bar = 10 μm. 
 
D. Microscopic observation of migrating platelets and bacterial capture 
1. Supplement modified Tyrode’s buffer pH 7.4 in a total volume of 240 μl with 104/μl human 
platelets, 1,000 μg/ml rHSA, 200 μM CaCl2, 2 μM U46619 and 4 μM ADP and add to above 
prepared channels coated with fibrin and live E. coli. 
Note: ADP, U46619 and CaCl2 synergistically trigger platelets activation and spreading. Albumin 
is an anti-adhesive protein that lowers substrate adhesiveness. 
2. Incubate the channel in Step D1 at 37 °C for 1 h and 20 min (Figure 4). 
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Figure 4. A representative image of migrating platelets collecting fibrin-bound E. coli. 
Fibrin and live E. coli coated channel was incubated with 104/μl human platelets in the presence 
of 1,000 μg/ml rHSA, 200 μM CaCl2, 2 μM U46619 and 4 μM ADP in modified Tyrode’s buffer 
at 37 °C for 1 h and 20 min. Images show phase contrast (A) and epifluorescent micrographs 
(B and C). The black area in the fibrin image (B) indicates the area cleared by migrating platelets. 
Scale bar = 10 μm. E. coli accumulated on platelets and bacteria density is reduced in areas 
where platelets migrated (D). 
 
3. Assemble the Ibidi channel with a fluid tube connected to the syringe pump and place it on an 
inverted microscope with a heated stage. 
Note: Always carefully rule out air bubbles in the syringe and tube before the perfusion. 
4. Perfuse the channel with pre-warmed (37 °C) modified Tyrode’s buffer (pH 7.4) at 0.5 dyne/cm2 
for 1 min to remove non-adhering bacteria and take phase contrast and epifluorescent images.  
Note: The flow rate Φ (ml/min) of the syringe pump is calculated by the following formulas 
provided by the instruction of sticky sides from Ibidi: 
 
τ = η x 97.1 x Φ 
τ: Shear stress (dyne/cm2) 
η: Dynamical viscosity (dyn s/cm2) 
 
The dynamical viscosity of cell culture medium at 37 °C is ~0.007. 
5. Perfuse the channel with modified Tyrode’s buffer (pH 7.4) at 37 °C at 5 dyne/cm2 for 5 min and 
take images (Figure 5). 
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6. Image acquisition: Filtercubes (Excitation/Emission): fibrin (Alexa 488) (494/528 nm); E. coli 
(tdTomato) (590/617 nm). 
Note: Deal with the waste of the perfusion buffer that contains bacteria properly according to 
the safety regulations. 
 
 
Figure 5. Representative images of bacteria trapped without platelets and with platelets 
after 0.5 dyne/cm2 and 5 dyne/cm2. The micrographs show the merged phase contrast and 
fluorescent images. Scale bars = 5 μm. 
Note: In the absence of platelets, the number of E. coli (magenta) on the fibrin (green) was 
reduced after perfusion. The white arrows indicate the E. coli that were flushed away. In contrast, 
the bacteria bundle collected by migrating platelets is resistant to shear stress. 
 
Data analysis 
 
1. Open the acquired images in FIJI software (Schindelin et al., 2012). 
2. Adjust brightness and contrast of each channel separately to clearly identify bacteria and fibrin 
fibers, respectively. 
3. Manually count fibrin-bound bacteria aggregates (in the presence and absence of platelets) 
before and after perfusion. 
4. Calculate the fraction of bacteria resistant to perfusion for each experiment by dividing the 
number of bacteria aggregates after perfusion by the number of bacteria before perfusion. As 
an example, the bar plot in Figure 6 shows flow resistance of bacterial aggregates in the 
presence and absence of platelets.  
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5. Test the statistical significance of your results. In the example shown in Figure 6 we repeated 
experiments 6 times and performed a Wilcox rank sum test to test for statistical significance (R 
software [R Development Core Team 2011]). 
 
 
Figure 6. Bar plots showing surface-bound bacterial aggregates after perfusion (5 
dyne/cm²) as fraction of initially bound bacteria (in %). Bacteria aggregates bound to 
platelets are more resistant to shear stress than bacteria aggregates bound to fibrin only. n = 6; 
Mean ± SEM; statistical significance was tested using the Wilcox rank sum test. 
 
Notes 
 
E. coli (DH 12)-strain used in this protocol requires safety level 1 (S1) laboratories. 
 
Recipes 
 
1. ACD buffer, pH 4.7 
85 mM Sodium citrate tribasic dehydrate 
65 mM citric acid monohydrate 
111 mM glucose 
2. Modified Tyrode’s buffer 
136.9 mM NaCl 
12.1 mM NaHCO3 
2.6 mM KCl 
5.5 mM glucose 
10 mM HEPES 
Note: Prepare 10x Tyrode’s buffer (1.37 mol NaCl, 121 mM NaHCO3, 26 mM KCl) and store at 
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4 °C. Dilute the stock Tyrode’s buffer with ddH2O and add glucose as well as HEPES buffer for 
daily use. Then adjust the pH to 6.5 for platelets isolation and 7.4 for platelet migration. 
3. Fibrin buffer 
Modified Tyrode’s buffer (pH 7.4) was supplemented with 300 μg/ml fibrinogen (1:10 mixed with 
Alexa488 conjugate fibrinogen), 12 mg/ml rHSA, 2 U/ml thrombin, and 1 mM CaCl2 
Note: Prepare the fibrin buffer just before use. 
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